Penn Capital Management Company LLC Acquires Shares of 153,877 Lantheus Holdings, Inc. $LNTH

Penn Capital Management Company LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 153,877 shares of the medical equipment provider’s stock, valued at approximately $17,089,000.

A number of other institutional investors also recently modified their holdings of the company. ABS Investment Management LLC bought a new stake in shares of Lantheus in the second quarter worth about $232,974,000. Versant Capital Management Inc raised its position in Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 146 shares during the last quarter. Abel Hall LLC raised its position in Lantheus by 4.6% during the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after purchasing an additional 172 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Lantheus by 6.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after buying an additional 202 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the topic of several research analyst reports. Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research note on Monday, June 29th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. B. Riley Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Finally, Brookline Capital Markets lowered shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $108.11.

Lantheus Stock Up 0.3%

LNTH stock opened at $100.77 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 24.34 and a beta of -0.03. The business’s 50 day moving average price is $103.74 and its two-hundred day moving average price is $91.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter last year, the business posted $1.57 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.